1상모집 예정
A Study of LY3971297 in Participants With Heart Failure
연구 개요
The main purpose of this study is to assess how well LY3971297 is tolerated and what side effects may occur in participants with heart failure with preserved ejection fraction (HFpEF) and participants with heart failure with reduced ejection fraction (HFrEF). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 2 months and will include 1 inpatient visit lasting approximately 4 days and 5 outpatient visits.
- 스폰서
- 리드: 일라이 릴리
- 적응증
- Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
- 중재
- LY3971297, LY3971297, Placebo, Placebo
- 목표 등록
- 90명
- 시작일
- 2026-08-01
- 완료(예정)
- 2027-11-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.